Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
Michael J. Joyner,R. Scott Wright,DeLisa Fairweather,Jonathon W. Senefeld,Katelyn A. Bruno,Stephen A. Klassen,Rickey E. Carter,Allan M. Klompas,Chad C. Wiggins,John R. A. Shepherd,Robert F. Rea,Emily R. Whelan,Andrew J. Clayburn,Matthew R. Spiegel,Patrick W. Johnson,Elizabeth R. Lesser,Sarah E. Baker,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,David O. Hodge,Katie L. Kunze,Matthew R. Buras,Matthew N.P. Vogt,Vitaly Herasevich,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Nigel Paneth,Nicole C. Verdun,Peter W. Marks,Arturo Casadevall +35 more
Reads0
Chats0
TLDR
Early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and given the deadly nature of COVID 19 and the large population of critically-ill patients, the mortality rate does not appear excessive.Abstract:
BACKGROUNDConvalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.METHODSThus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent plasma.RESULTSThe incidence of all serious adverse events (SAEs), including mortality rate (0.3%), in the first 4 hours after transfusion was <1%. Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n = 4), transfusion-associated circulatory overload (n = 7), transfusion-related acute lung injury (n = 11), and severe allergic transfusion reactions (n = 3). However, only 2 of 36 SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The 7-day mortality rate was 14.9%.CONCLUSIONGiven the deadly nature of COVID-19 and the large population of critically ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.TRIAL REGISTRATIONClinicalTrials.gov NCT04338360.FUNDINGMayo Clinic, Biomedical Advanced Research and Development Authority (75A50120C00096), National Center for Advancing Translational Sciences (UL1TR002377), National Heart, Lung, and Blood Institute (5R35HL139854 and R01 HL059842), National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352), Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019), National Institute of Allergy and Infectious Disease (R21 AI145356, R21 AI152318, and AI152078), Schwab Charitable Fund, United Health Group, National Basketball Association, Millennium Pharmaceuticals, and Octapharma USA Inc.read more
Citations
More filters
Journal ArticleDOI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb,Ajay Nirula,Peter Chen,Joseph Boscia,Barry Heller,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Lei Shen,Daniel Skovronsky +26 more
TL;DR: The BLAZE-1 trial as mentioned in this paper evaluated the effect of bamlanivimab monotherapy and combination therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Journal ArticleDOI
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
Romina Libster,Gonzalo Pérez Marc,Diego Wappner,Silvina Coviello,Alejandra Bianchi,Virginia Braem,Ignacio Esteban,Mauricio T. Caballero,Cristian Wood,Mabel Berrueta,Anibal Rondan,Gabriela Lescano,Pablo Cruz,Yvonne Ritou,Valeria Fernandez Vina,Damian Alvarez Paggi,Sebastian Esperante,Adrián Ferreti,Gaston Ofman,Alvaro Ciganda,Rocio Rodriguez,Jorge Lantos,Ricardo Valentini,Nicolas Itcovici,Alejandra Hintze,M Laura Oyarvide,Candela Etchegaray,Alejandra Neira,Ivonne Name,Julieta Alfonso,Rocio Lopez Castelo,Gisela Caruso,Sofia Rapelius,Fernando Alvez,Federico Cesar Etchenique,Federico Dimase,Dario Raul Alvarez,Sofia Sol Aranda,Clara Sanchez Yanotti,Julian De Luca,Sofia Jares Baglivo,Sofia Lujan Laudanno,Florencia Nowogrodzki,Ramiro Manuel Larrea,Maria Dolores Silveyra,Gabriel Leberzstein,Alejandra Debonis,Juan Molinos,Miguel Santiago Gonzalez,Eduardo Perez,Nicolás Kreplak,Susana Pastor Arguello,Luz Gibbons,Fernando Althabe,Eduardo Bergel,Fernando P. Polack +55 more
TL;DR: In this paper, a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms was conducted.
Journal ArticleDOI
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
TL;DR: Key ADE mechanisms are described and mitigation strategies for SARS-CoV-2 vaccines and therapies in development are discussed and recently published data is outlined to evaluate the risks and opportunities for antibody-based protection against Sars-Cov-2.
Journal ArticleDOI
Aging in COVID-19: Vulnerability, immunity and intervention.
Yiyin Chen,Sabra L. Klein,Brian T. Garibaldi,Huifen Li,Cunjin Wu,Nicole M. Osevala,Taisheng Li,Joseph B. Margolick,Graham Pawelec,Sean X. Leng +9 more
TL;DR: It is hypothesized that age-related decline and dysregulation of immune function, i.e., immunosenescence and inflammaging play a major role in contributing to heightened vulnerability to severe COVID-19 outcomes in older adults and partitioning all immunological outcome data by age to better understand disease heterogeneity and aging.
Journal Article
Meta-analysis: Convalescent blood products for spanish influenza pneumonia : A future H5N1 treatment? Commentary
TL;DR: To assess the potential treatment efficacy of convalescent plasma in reducing mortality in current patients with H5N1 influenza, a review of studies from the Spanish influenza era that used influenza-convalescent human blood products to treat patients with Spanish influenza complicated by pneumonia was conducted.
References
More filters
Journal ArticleDOI
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris,Robert W. Taylor,Robert J. Thielke,Jonathon Payne,Nathaniel Gonzalez,José G. Conde +5 more
TL;DR: Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data Capture tools to support clinical and translational research.
Journal ArticleDOI
The REDCap consortium: Building an international community of software platform partners.
Paul A. Harris,Paul A. Harris,Robert Taylor,Brenda L. Minor,Veida Elliott,Michelle Fernandez,Lindsay O'Neal,Laura McLeod,Giovanni Delacqua,Francesco Delacqua,Jacqueline Kirby,Stephany N. Duda +11 more
TL;DR: The Research Electronic Data Capture (REDCap) data management platform was developed in 2004 to address an institutional need at Vanderbilt University, then shared with a limited number of adopting sites beginning in 2006, and a broader consortium sharing and support model was created.
Journal ArticleDOI
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Xiaobo Yang,Yuan Yu,Jiqian Xu,Huaqing Shu,Jia'an Xia,Hong Liu,Hong Liu,Yongran Wu,Lu Zhang,Zhui Yu,Minghao Fang,Ting Yu,Yaxin Wang,Shangwen Pan,Xiaojing Zou,Shiying Yuan,You Shang,You Shang +17 more
TL;DR: The clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital between late December, 2019 and Jan 26, 2020 are described.
Journal ArticleDOI
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
Safiya Richardson,Safiya Richardson,Jamie S. Hirsch,Jamie S. Hirsch,Mangala Narasimhan,James M. Crawford,Thomas McGinn,Thomas McGinn,Karina W. Davidson,Karina W. Davidson,Douglas P. Barnaby,Douglas P. Barnaby,Lance B Becker,John Chelico,John Chelico,Stuart L. Cohen,Stuart L. Cohen,Jennifer Cookingham,Kevin Coppa,Michael A Diefenbach,Andrew J. Dominello,Joan Duer-Hefele,Louise Falzon,Jordan Gitlin,Negin Hajizadeh,Negin Hajizadeh,Tiffany G. Harvin,David Hirschwerk,Eun Ji Kim,Eun Ji Kim,Zachary Kozel,Lyndonna Marrast,Lyndonna Marrast,Jazmin N. Mogavero,Gabrielle A. Osorio,Michael Qiu,Theodoros P. Zanos +36 more
TL;DR: This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area and assesses outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death.
Journal ArticleDOI
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.
Pavan K. Bhatraju,Bijan J Ghassemieh,Michelle Nichols,Richard Kim,Keith R. Jerome,Arun K. Nalla,Alexander L. Greninger,Sudhakar Pipavath,Mark M Wurfel,Laura Evans,Patricia M Kritek,T. Eoin West,Andrew M Luks,Anthony Gerbino,Christopher R. Dale,Jason D Goldman,D. Shane O’Mahony,Carmen Mikacenic +17 more
TL;DR: During the first 3 weeks of the Covid-19 outbreak in the Seattle area, the most common reasons for admission to the ICU were hypoxemic respiratory failure leading to mechanical ventilation, hypotension requiring vasopressor treatment, or both.
Related Papers (5)
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
Ling Li,Zhang Wei,Yu Hu,Xunliang Tong,Shangen Zheng,Juntao Yang,Yujie Kong,Lili Ren,Qing Wei,Heng Mei,Caiying Hu,Cuihua Tao,Ru Yang,Jue Wang,Yongpei Yu,Guo Yong,Xiaoxiong Wu,Zhihua Xu,Li Zeng,Nian Xiong,Lifeng Chen,Juan Wang,Ning Man,Yu Liu,Haixia Xu,E. Deng,Xuejun Zhang,Chenyue Li,Conghui Wang,Shisheng Su,Linqi Zhang,Jianwei Wang,Yanyun Wu,Zhong Liu +33 more
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Kai Duan,Bende Liu,Li Cesheng,Huajun Zhang,Ting Yu,Jieming Qu,Min Zhou,Li Chen,Shengli Meng,Hu Yong,Cheng Peng,Mingchao Yuan,Jinyan Huang,Zejun Wang,Jianhong Yu,Xiaoxiao Gao,Dan Wang,Xiaoqi Yu,Li Li,Jiayou Zhang,Xiao Wu,Bei Li,Yanping Xu,Wei Chen,Peng Yan,Yeqin Hu,Lin Lianzhen,Xuefei Liu,Shihe Huang,Zhou Zhijun,Lianghao Zhang,Yue Wang,Zhang Zhi,Kun Deng,Zhiwu Xia,Gong Qin,Wei Zhang,Xiaobei Zheng,Ying Liu,Huichuan Yang,Dongbo Zhou,Ding Yu,Jifeng Hou,Zhengli Shi,Sai-Juan Chen,Zhu Chen,Xinxin Zhang,Xiaoming Yang +47 more
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Chenguang Shen,Zhaoqin Wang,Fang Zhao,Yang Yang,Jinxiu Li,Jing Yuan,Fuxiang Wang,Delin Li,Delin Li,Minghui Yang,Li Xing,Jinli Wei,Haixia Xiao,Haixia Xiao,Yan Yang,Jiuxin Qu,Ling Qing,Li Chen,Zhixiang Xu,Ling Peng,Yanjie Li,Haixia Zheng,Feng Chen,Kun Huang,Yujing Jiang,Dongjing Liu,Zheng Zhang,Yingxia Liu,Lei Liu +28 more
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
John Mair-Jenkins,Maria Saavedra-Campos,J Kenneth Baillie,Paul Cleary,Fu-Meng Khaw,Wei Shen Lim,Sophia Makki,Kevin Rooney,Jonathan S. Nguyen-Van-Tam,Charles R. Beck,Ana Mateus,Simone Reuter,Jinho Shin,Xiaolin Xu,Dmitriy Pereyaslov,Irina Papieva,Anders Tegnell,Hélène Englund,Åsa Elfving,Rebecca Jane Cox,Kristin G.-I. Mohn,Yingjie Feng Jenkins +21 more